BRPI0407747A - agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6 - Google Patents

agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6

Info

Publication number
BRPI0407747A
BRPI0407747A BRPI0407747-4A BRPI0407747A BRPI0407747A BR PI0407747 A BRPI0407747 A BR PI0407747A BR PI0407747 A BRPI0407747 A BR PI0407747A BR PI0407747 A BRPI0407747 A BR PI0407747A
Authority
BR
Brazil
Prior art keywords
antagonist
therapeutic agent
spinal cord
cord injury
interleukin
Prior art date
Application number
BRPI0407747-4A
Other languages
English (en)
Inventor
Hideyuki Okano
Seiji Okada
Masaya Nakamura
Kasuyuki Yoshizaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ Keio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Univ Keio filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0407747A publication Critical patent/BRPI0407747A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"AGENTE TERAPêUTICO PARA LESãO á MEDULA ESPINHAL COMPREENDENDO ANTAGONISTA DE INTERLEUCINAS-6". A presente invenção refere-se a um agente terapêutico para lesão de medula espinhal, um modulador de diferenciação de células tronco neurais e um inibidor de diferenciação em células gliais compreendendo um antagonista de interleucina-6 como um ingrediente ativo.
BRPI0407747-4A 2003-02-24 2004-02-24 agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6 BRPI0407747A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003046214 2003-02-24
PCT/JP2004/002111 WO2004073741A1 (ja) 2003-02-24 2004-02-24 インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤

Publications (1)

Publication Number Publication Date
BRPI0407747A true BRPI0407747A (pt) 2006-02-14

Family

ID=32905544

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407747-4A BRPI0407747A (pt) 2003-02-24 2004-02-24 agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6

Country Status (16)

Country Link
US (1) US20060165696A1 (pt)
EP (1) EP1607100A4 (pt)
JP (1) JP4555924B2 (pt)
KR (1) KR101142624B1 (pt)
CN (2) CN100340294C (pt)
AU (1) AU2004212843B2 (pt)
BR (1) BRPI0407747A (pt)
CA (1) CA2516945A1 (pt)
HR (1) HRP20050837A2 (pt)
IL (3) IL170399A (pt)
MX (1) MXPA05008713A (pt)
NO (1) NO20054072L (pt)
NZ (1) NZ541928A (pt)
PL (1) PL378199A1 (pt)
RU (2) RU2358761C2 (pt)
WO (1) WO2004073741A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7709215B2 (en) * 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP6097702B2 (ja) 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
KR20220064039A (ko) 2020-11-11 2022-05-18 정성삼 척수 손상 예방 또는 치료용 조성물
KR102320780B1 (ko) 2021-01-29 2021-11-02 정성삼 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
DK0811384T3 (da) * 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
EP1027059A2 (en) * 1997-10-27 2000-08-16 Curis, Inc. Enhancement of morphogen activity
JP2002503460A (ja) * 1998-02-13 2002-02-05 ザ ウィスター インスティテュート 創傷治癒のための組成物および方法
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders

Also Published As

Publication number Publication date
HK1088230A1 (zh) 2006-11-03
JPWO2004073741A1 (ja) 2007-08-23
US20060165696A1 (en) 2006-07-27
EP1607100A4 (en) 2007-06-13
RU2005130011A (ru) 2006-02-10
RU2358761C2 (ru) 2009-06-20
NO20054072D0 (no) 2005-09-01
WO2004073741A8 (ja) 2005-04-07
PL378199A1 (pl) 2006-03-06
HRP20050837A2 (en) 2005-12-31
NO20054072L (no) 2005-10-25
KR101142624B1 (ko) 2012-06-15
RU2009102845A (ru) 2010-08-10
EP1607100A1 (en) 2005-12-21
CN101130077A (zh) 2008-02-27
CA2516945A1 (en) 2004-09-02
IL200098A (en) 2012-10-31
IL205618A (en) 2012-02-29
NZ541928A (en) 2009-06-26
WO2004073741A1 (ja) 2004-09-02
CN100340294C (zh) 2007-10-03
CN1753694A (zh) 2006-03-29
AU2004212843A1 (en) 2004-09-02
IL170399A (en) 2011-02-28
JP4555924B2 (ja) 2010-10-06
AU2004212843B2 (en) 2009-06-25
KR20060006004A (ko) 2006-01-18
MXPA05008713A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
NO20054072L (no) Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.
WO2002098890A3 (en) MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
DE60237431D1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
ECSP066759A (es) Combinaciones de productos activos insecticidas a base de thiacloprid y de piretroides
ATE415817T1 (de) Agrochemische formulierungen
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
IL172396A0 (en) Replikin peptides and uses thereof
EP2359832A3 (en) Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
BR0210650A (pt) Tablete, e, uso do mesmo
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
BRPI0414114A (pt) uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung
ATE411053T1 (de) Albuminkonjugate, die eine glucuron-verknüpfung enthalten
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
IL172416A0 (en) Modified human acid sphingomyelinase having increased activity, and methods for making the same
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
EP1563836A4 (en) ACTIVE SUBSTANCE FOR INHIBITING MATRIX METALOPROTEASE-9 PRODUCTION

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.